Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | POLM | Q9NP87 | 1/20 | 0.46 |
| ▸ | POLK | Q9UBT6 | 1/20 | 0.46 |
| ▸ | POLL | Q9UGP5 | 1/20 | 0.46 |
| ▸ | POLH | Q9Y253 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32684489 | 0.98 | KMT2A (0.56) | CYP3A4KMT2ASMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL9538006 | 0.98 | KMT2A (0.56) | CYP3A4KMT2ASMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL9716546 | 0.98 | KMT2A (0.56) | CYP3A4KMT2ASMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL6139167 | 0.98 | KMT2A (0.56) | CYP3A4KMT2ASMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL4079668 | 0.95 | CYP3A4 (0.57) | CYP3A4KMT2ASMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL689823 | 0.92 | CYP3A4 (0.59) | CYP3A4KMT2ASMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL16974801 | 0.91 | POLM (0.54) | KMT2ASMN1; SMN2MEN1ALDH1A1MAPK1 | |
| SCHEMBL16974800 | 0.91 | POLM (0.54) | KMT2ASMN1; SMN2MEN1ALDH1A1MAPK1 | |
| SCHEMBL10407331 | 0.90 | KMT2A (0.60) | KMT2ASMN1; SMN2MEN1ALDH1A1MAPK1 | |
| SCHEMBL688275 | 0.90 | CYP3A4 (0.58) | CYP3A4KMT2ASMN1; SMN2MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0687249-A1 | BALANOIDS | ELI LILLY AND COMPANY (US) | 1995-12-20 | — | — | EP | claimed |
| WO-1994020062-A2 | BALANOIDS AS PROTEIN KINASE C INHIBITORS | ELI LILLY AND COMPANY (US) | 1994-09-15 | — | — | WO | claimed |
| CN-108265007-A | The application of deep-sea fungi 3A00421 and its fermented cpds | 国家海洋局第三海洋研究所 | 2018-07-10 | — | — | CN | disclosed |
| EP-2152685-B1 | SKIN LIGHTENING COMPOSITIONS AND METHODS | SYTHEON LTD (US) | 2017-01-25 | — | — | EP | disclosed |
| EP-2152685-A1 | SKIN LIGHTENING COMPOSITIONS AND METHODS | Sytheon Ltd. (US) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008153629-A1 | SKIN LIGHTENING COMPOSITIONS AND METHODS | SYTHEON LTD. (US) | 2008-12-18 | — | — | WO | disclosed |
| US-20080305059-A1 | Skin lightening compositions and methods | SYTHEON LIMITED | 2008-12-11 | — | — | US | disclosed |
| US-20060129002-A1 | Process for the synthesis of alkylresorcinols | HONEYWELL INTERNATIONAL INC. | 2006-06-15 | — | — | US | disclosed |
| EP-0687249-A1 | BALANOIDS | ELI LILLY AND COMPANY (US) | 1995-12-20 | — | — | EP | disclosed |
| WO-1994020062-A2 | BALANOIDS AS PROTEIN KINASE C INHIBITORS | ELI LILLY AND COMPANY (US) | 1994-09-15 | — | — | WO | disclosed |
| EP-0341664-B1 | SKIN DEPIGMENTAL AGENT | KURARAY CO., LTD. (JP) | 1992-08-05 | — | — | EP | disclosed |
| US-4959393-A | ALKYL-SUBSTITUTED RESORCINOL | KURARAY COMPANY, LTD. (JP) | 1990-09-25 | — | — | US | disclosed |
| EP-0341664-A1 | Skin depigmental agent | KURARAY CO., LTD. (JP) | 1989-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060129002-A1 | Process for the synthesis of alkylresorcinols | ACSL4, ZDHHC20, ACSL6 | CYP3A4 264/4885KMT2A 483/4885SMN1; SMN2 4373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.